

Special Issue

Prostate Cancer Genetics and the Emergence of Targeted Therapies Based on Molecular Profiling

Message from the Guest Editors

Our understanding of the genetic basis of prostate cancer has increased considerably over the last decade. Two recent studies have shown that approximately 30% of familial relative risk is explained by common variants, discovered through GWAS and fine-mapping efforts. However, the true clinical utility of these variants is yet to be revealed in terms of patient stratification. To uncover some of the ‘missing heritability’, NGS methodologies are being used for rare variant discovery, which promises to identify more functionally relevant risk variants. Combined with patient stratification, this approach can also be used to discover rare variants associated with aggressive or fatal prostate cancer. Furthermore, molecular profiling of rare variants at both germline and somatic levels, including circulating tumour cells, can identify biomarkers that predict patient response to targeted therapies (i.e., pharmacogenomics). We extend an invitation for reviews and research articles on the discovery of rare prostate cancer variants, particularly those that can be used to distinguish clinically relevant disease or predict therapeutic efficacies and outcomes.

Guest Editors

Dr. Liesel FitzGerald

Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia

Dr. Csilla Sipeky

University of Turku, Institute of Biomedicine, 20520 Turku, Finland

Deadline for manuscript submissions

closed (31 May 2019)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/18108

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))